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MinireviewDrug and Gene Delivery to the Brain:
The Vascular Route
of the BBB is very thin, and the total intracellular volume
of the brain capillary endothelium is only 5 ml in the
entire human brain and 1l in the rat brain. The thickness
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of the brain capillary endothelial cell is about 200–300University of California, Los Angeles
nm. This very thin cellular barrier has some of the mostLos Angeles, California 90024
restrictive permeability properties of any biological
membrane (Oldendorf, 1971).
Multifunctional Basis of BBB to Drugs. Drug entryBrain drug development of either small molecule or
into brain from blood is restricted at the BBB throughlarge molecule (recombinant proteins, gene medi-
multiple mechanisms, including a physical endothelialcines) neurotherapeutics has been limited, owing to
barrier, an enzymatic BBB, and an efflux barrier. Thisthe restrictive transport properties of the brain micro-
multifunctionality of the BBB arises from the multicellu-vasculature, which forms the blood-brain barrier (BBB)
larity of the brain microvasculature, which is formed byin vivo. Widespread drug delivery to the brain, while
the triad of brain capillary endothelial cells, capillarynot feasible via craniotomy and intracerebral injection,
pericytes, and perivascular astrocyte foot processesis possible if the drug is delivered to brain via the
(Pardridge, 2001). The endothelium and pericyte sharetransvascular route through the BBB. Novel brain drug
a common microvascular basement membrane, anddelivery and drug targeting strategies can be devel-
99% of the brain surface of the capillary basement mem-oped from an understanding of the molecular and cel-
brane is invested by the end-feet of processes extendinglular biology of the brain microvascular and BBB trans-
from astrocyte cell bodies originating within brain paren-port processes.
chyma.
Endothelial Tight Junctions. Capillaries perfusing pe-Introduction
ripheral organs have porous endothelial walls. Periph-Brain drug delivery is the rate-limiting step in the transla-
eral capillaries have open interendothelial junctionaltion of progress in the molecular neurosciences into
spaces and active pinocytosis, which form a paracellularclinically effective neurotherapeutics for patients with
route and a transcellular route, respectively, for the freedisorders of the central nervous system (CNS). Progress
diffusion of molecules from the blood to the organ inter-in brain drug delivery has lagged behind other areas in
stitium. However, in the vertebrate brain, the capillarythe molecular neurosciences, because of the difficulties
endothelial cells express epithelial-like high resistanceposed by the blood-brain barrier (BBB). The brains of
tight junctions, which eliminate the paracellular path-all vertebrates are perfused by a dense microvascular
way, and have minimal pinocytosis, which eliminatesnetwork, which is formed by the capillary endothelial
the nonspecific transcellular route of molecular trans-cells within the brain (Bar, 1980).
port from blood to brain (Brightman, 1977). The combi-The density of the microvasculature of the brain is
nation of the very high resistance endothelial tight junc-illustrated with the India ink injection study in the adult
tions and the minimal endothelial pinocytosis forms arat brain shown in Figure 1A. The capillary network in
physical barrier to drug entry into brain from blood.the brain is so intricate that no neuron or glial cell is
Enzymatic BBB. There is an “enzymatic BBB” to circu-more than 20 m from a neighboring capillary. There-
lating drugs, in addition to the physical barrier formed byfore, every neuron is virtually perfused by its own mi-
the endothelial tight junctions. The capillary endothelialcrovessel. Once a circulating neurotherapeutic crosses
cells, the capillary pericytes, and the astrocyte foot pro-
the brain microvascular wall, the drug or gene is immedi-
cesses all express a variety of ecto-enzymes on the
ately delivered to the “doorstep” of every neuron within
cellular plasma membranes, including aminopeptidases,
the brain. carboxypeptidases, endopeptidases, cholinesterases,
Brain Barrier Systems. In addition to the brain micro- and others, which inactivate many drugs that may pass
vascular endothelial barrier, which forms the BBB, there the endothelial barrier. For example, circulating adeno-
are other barrier systems within the CNS, including the sine enters brain from blood via the BBB concentrative
arachnoid epithelial membrane, which covers the sur- nucleoside transporter type 2 (CNT2) but does not have
face of the brain, and the choroid plexus epithelium, pharmacological effects in the brain, owing to rapid in-
which forms the blood-cerebrospinal fluid (CSF) barrier. activation at the BBB by adenosine metabolizing en-
In humans, there are approximately 400 miles of capillar- zymes (Pardridge, 2001). Conversely, the enzymatic
ies perfusing the brain, and the surface area of the brain BBB may serve to activate pro-drugs. Circulating
microvascular endothelium is approximately 20 m2 (Par- L-DOPA enters brain via the BBB large neutral amino
dridge, 2001), which is 1000-fold greater than the surface acid transporter type 1 (LAT1) and is rapidly converted
area of either the blood-CSF barrier or the arachnoid to dopamine, the pharmacologically active form of the
membrane (Dohrmann, 1970). Therefore, the quantita- drug, by microvascular aromatic amino acid decarboxyl-
tively important barrier system within the brain is the ase (AAAD).
BBB at the capillary endothelium (Figure 1A). Despite Active Efflux Barrier. Certain drugs may cross the en-
the vast surface area of the human BBB, the thickness dothelial barrier via free diffusion and undergo influx
from the blood to the brain compartment. However, this
influx can be immediately followed by active efflux from1Correspondence: wpardridge@mednet.ucla.edu
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cules can traverse the BBB nonspecifically via lipid-
mediated transport. A misconception with respect to
small molecule transport across the BBB is that if a
molecule is “small,” then BBB transport is unrestricted.
Only small molecules that are (1) lipid soluble and (2)
have a molecular weight 500 Da threshold cross the
BBB in pharmacologically significant amounts (Par-
dridge, 2001). Virtually all drugs presently in CNS clinical
practice are small molecules that have these dual molec-
ular characteristics. Similarly, if a small molecule is water
soluble or has a molecular weight 500 Da, the drug
may not cross biological barriers in pharmacologically
significant amounts and have reduced absorption, as
predicted by the “Rule of 5” (Lipinski et al., 1997). The
adverse effect of molecular weight on membrane perme-
ation is not observed if the molecular weight of the drug
is 400 Daltons (Habgood et al., 2000). However, if the
molecular weight of the drug causes the surface area of
the drug to exceed 50–100 angstroms2, then membrane
permeation of the drug will not increase in proportion
to the increase in lipid solubility of the drug (Fischer et
al., 1998). The dependence of drug permeation through
biological membranes on either molecular volume or
molecular weight is not predicted by measurements of
drug partitioning in solvents, because drug diffusionFigure 1. Transvascular and Transcranial Drug Delivery to the Brain
through solvents is not identical to drug diffusion across(A) India ink injection in adult rats shows the dense microvascular
biological membranes (Lieb and Stein, 1986). Lipid me-network within the brain (Bar, 1980). These brain capillaries form
the BBB, and the delivery of drugs or genes across the BBB is the diation of small molecules through biological mem-
only pathway that enables widespread distribution of the drug to branes requires molecular movement through channels
all cells within the brain. within the lipid bilayer, and these channels have a finite
(B) Film autoradiogram of rat brain 48 hr after the intracerebral size (references can be found in Pardridge, 2001). In
(IC) implantation of a biodegradable polymer containing [125I]-nerve
summary, there are multiple impediments to small mole-growth factor (NGF) (Krewson et al., 1995). The distance bar is 2.5
cule transport across the BBB, and the following charac-mm, and the diameter of the polymer was 2 mm; therefore, there is
minimal diffusion of the NGF into brain away from the IC implant. teristics are associated with reduced BBB transport and
(C) Film autoradiogram of rat brain 24 hr after the ICV injection of reduced in vivo CNS pharmacologic activity:
[125I]-BDNF (Yan et al., 1994). The neurotrophin does not distribute
into brain beyond the ipsilateral ependymal surface. • Molecular weight 500 Daltons
• Sum of hydrogen bond donor/acceptor groups 10
brain back to blood if the drug is a substrate for one of • Substrate for BBB enzyme system
many different active efflux transporters (AET) ex-
• Substrate for BBB active efflux transporterpressed within the brain microvasculature. P-glycopro-
tein is the model AET at the BBB (Tsuji and Tamai, 1999), • Avid plasma protein binding of the drug
but there are many other efflux systems, such as organic
anion transporting polypeptide type 2 (oatp2) (Asaba et
The above factors make it difficult to design a smallal., 2000). One strategy to increase drug uptake into
molecule drug with effective CNS activity. Current smallbrain is the development of “co-drugs” (Pardridge,
molecule neuropharmaceuticals only effectively treat a2001). Co-drugs are inhibitors of BBB AET systems and
few CNS disorders, including pain, epilepsy, insomnia,are coadministered with the pharmacologically active
and affective disorders (Ajay et al., 1999), and the major-drug that is an AET substrate. This is analogous to the
ity of CNS disorders have thus far proven refractory toadministration of an AAAD-inhibitor with L-DOPA to pre-
conventional small molecule therapy. A principal reasonvent early degradation of the drug. In this case, the
for this failure of conventional drug therapy of the brainAAAD-inhibitor should be a drug that does not cross
is that 98% of all small molecule drug candidates dothe BBB and selectively inhibits AAAD in the periphery.
not cross the BBB, and no BBB drug targeting technologyOwing to these unique barrier properties of the micro-
is used by the pharmaceutical industry (Pardridge, 2001).vascular endothelial barrier in the vertebrate brain, circu-
Catalyzed Transport via CMT and RMT Systems. Smalllating molecules in the blood gain access to brain inter-
water-soluble nutrients and vitamins traverse the BBBstitial space via only one of two transport mechanisms:
rapidly via carrier-mediated transport (CMT). The CMT
systems generally mediate the blood-to-brain transport• Lipid-mediated free diffusion of small molecules
of nutrients and include the GLUT1 glucose transporter,
• Catalyzed transport of small or large molecules the LAT1 large neutral amino acid transporter, the MCT1
monocarboxylic acid transporter, the CNT2 nucleoside
transporter, and many other small molecule transportersFree Diffusion of Small Molecules. Certain small mole-
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(references can be found in Pardridge, 2001). The CMT the membrane, and this induces absorptive-mediated
endocytosis into the cell (Pardridge, 2001). Proteins maysystems are portals of entry of small molecule drugs
that have a molecular structure similar to endogenous be cationized via either (1) conjugation of amino groups
such as hexamethylenediamine to surface carboxyl moi-nutrients. L-DOPA, a neutral amino acid, gains access
to the brain via CMT on the BBB large neutral amino eties, or (2) conjugation of cationic “import” peptides
such as the arginine-rich tat peptide (Schwarze et al.,acid transporter. In contrast, the conjugation of glucose
to a peptide does not mediate transport via the BBB 1999). Protein cationization has the same effect as drug
lipidization. Both processes increase BBB permeabilityGLUT1 carrier (Witt et al., 2001), because the GLUT1
transporter does not recognize the peptide structure. In for the drug or protein but also cause a parallel increase
in peripheral organ uptake and concomitant decreaseaddition to the CMT systems, certain large molecule
peptides or plasma proteins are selectively transported in the plasma concentration of the drug or protein.
Therefore, the brain uptake does not increase in propor-across the BBB via receptor-mediated transport (RMT)
systems, including the insulin receptor, the transferrin tion to the increase in BBB transport following protein
cationization (Lee and Pardridge, 2001).receptor (TfR), or the leptin receptor. RMT of circulating
peptides is comprised of three sequential steps: (1) re- Chimeric Peptides. A chimeric peptide is formed when
a small or large molecule drug that is normally not trans-ceptor-mediated endocytosis of the circulating peptide
at the luminal membrane of the capillary endothelium, ported across the BBB is fused or conjugated to a BBB
transport vector. The latter is comprised of an endoge-(2) movement through the 200–300 nm of endothelial
cytoplasm, and (3) exocytosis of the peptide into the nous peptide, modified protein, or peptidomimetic mono-
clonal antibody (MAb) that undergoes RMT through thebrain interstitial fluid at the abluminal membrane of the
capillary endothelium (Pardridge, 2001). BBB on endogenous endothelial receptor systems (Par-
dridge, 2001). A peptidomimetic MAb transport vectorBrain Drug Delivery Strategies
Craniotomy-Based Drug Delivery to the Brain. Drugs or binds an exofacial epitope on the BBB receptor. The
MAb epitope is removed from the endogenous ligandgenes may be delivered to the brain via either intracere-
broventricular (ICV) injection or intracerebral implanta- binding site, and this binding enables the MAb to “piggy-
back” across the BBB on the endogenous RMT system,tion (Shoichet and Winn, 2000). However, drug entry into
brain parenchyma with either approach is limited by as demonstrated by electron microscopy of brain follow-
ing the in vivo perfusion of anti-receptor MAb-gold con-diffusion, and little drug diffuses into brain far from the
depot site (Figures 1B and 1C). The most direct ap- jugates. The MAb acts as a transport vector and can
deliver to the brain any attached drug or gene. A panelproach to drug or gene delivery to all parts of the brain
is the vascular route (Figure 1A), and the transvascular of species-specific peptidomimetic MAbs has been de-
veloped to allow for transport of drugs or genes into thebrain drug delivery strategies include hyperosmolar BBB
disruption, drug lipidization, protein cationization, and brain of either animal models or humans (references can
be found in Pardridge, 2001).the chimeric peptide technology.
Hyperosmolar BBB Disruption. The intracarotid arte- Brain Drug Delivery of Large Molecule Drugs
Large molecule drugs are peptides, recombinant pro-rial infusion of hyperosmolar solutions causes a shrink-
ing of the brain and the brain capillary endothelium, and teins, antisense agents, and gene medicines. It is widely
believed that the BBB transport of large molecule drugsthis leads to a transient disruption of the BBB (Shoichet
and Winn, 2000). BBB disruption has been used in hu- is not possible, and large molecule drug development
programs are frequently terminated in favor of smallmans for the delivery of chemotherapeutic agents to
brain cancer (Dahlborg et al., 1998). The concern with molecule drug discovery. However, recombinant pro-
teins, antisense drugs, and non-viral gene medicinesBBB disruption is that this causes a generalized increase
in the brain uptake of many plasma constituents. Blood can be delivered to the brain with brain drug targeting
technology.proteins are toxic to brain cells (Nadal et al., 1995), and
hyperosmolar BBB disruption causes chronic neuro- Recombinant Proteins. Neurotrophins could be used
for a wide variety of brain diseases, but these recombi-pathologic changes (Salahuddin et al., 1988).
Drug Lipidization. The BBB permeability-surface area nant proteins do not cross the BBB in pharmacologically
significant amounts. Consequently, virtually all current(PS) product is an experimental measure of BBB perme-
ability to a given drug. The BBB PS product for small neurotrophin CNS drug development programs are fo-
cused on the discovery of small molecule peptidomimet-molecules may be increased with lipidization via either
(1) the reduction in hydrogen bonding of the drug ics. However, most small molecule peptidomimetics will
not have molecular characteristics that pass the strin-through conjugation of lipid-soluble functional groups
to water-soluble moieties on the drug, or (2) conjugation gent criteria discussed above for effective BBB trans-
port. Therefore, the small molecule peptidomimeticof the drug to a lipid carrier such as free fatty acid,
adamantane, or dihyropyridine. A problem with drug would benefit from reformulation with a BBB drug deliv-
ery strategy to be pharmacologically active in the brain.lipidization is that the uptake of the lipidized drug by
peripheral organs is also increased, and this causes The development of a small molecule drug that crosses
the BBB can be just as difficult as the development ofa reduction in the plasma concentration of the drug.
Therefore, the increased BBB transport caused by lipidi- a large molecule drug that is transported across the
BBB. Therefore, one alternative is to reformulate thezation is offset by the increased uptake of the drug by
peripheral tissues (Pardridge, 2001). large molecule drug with a BBB drug delivery strategy.
This has been done with the chimeric peptide technol-Protein Cationization. The cellular uptake of proteins
may be increased by cationizing the protein, which trig- ogy, wherein a nontransportable peptide is conjugated
to a BBB transport vector, which functions as a molecu-gers electrostatic interactions with anionic groups on
Neuron
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Drug Development (Cambridge, UK: Cambridge University Press).low molecular weight metabolites form in blood, which
Salahuddin, T.S., Johansson, B.B., Kalimo, H., and Olsson, Y. (1988).then enter brain to account for the cerebral uptake of
Acta Neuropathol. (Berl). 77, 5–13.radioactivity. When the peripheral metabolism of the pep-
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Gene Medicines. Widespread distribution of a thera-
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peutic gene to brain, particularly the human brain, can
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only be achieved by delivery via the transvascular route (2001). Peptides 22, 2329–2343.
(Figure 1A). It is possible to deliver non-viral plasmid Yan, Q., Matheson, C., Sun, J., Radeke, M.J., Feinstein, S.C., and
DNA throughout the brain with gene targeting technol- Miller, J.A. (1994). Exp. Neurol. 127, 23–36.
ogy that uses pegylated immunoliposomes (PIL), which Zhang, Y., Zhu, C., and Pardridge, W.M. (2002). Mol. Ther. 6, 67–72.
are able to access endogenous RMT systems within the
BBB (references can be found in Zhang et al., 2002). In
this approach, the supercoiled non-viral plasmid DNA
is encapsulated in the interior of an 85 nm liposome,
and this encapsulation within a nanocontainer protects
the DNA from the ubiquitous endonucleases in the body
in vivo. Uptake of the liposome by the reticulo-endothe-
lial system (RES) is minimized by conjugating several
thousand strands of 2000 Da polyethyleneglycol (PEG)
to the surface of the liposome. The PIL is targeted across
the BBB and across brain cell membranes by attaching
receptor-specific MAbs to the tips of 1%–2% of the
PEG strands. With this approach to brain gene delivery,
intravenous antisense gene therapy led to a 100% in-
crease in survival time in animals with experimental hu-
man brain cancer (Zhang et al., 2002).
Summary. The delivery of virtually any pharmaceutical
to the brain via the vascular route is possible with the
use of brain drug and gene targeting technology. The
development of neurotherapeutics of the future can be
accelerated by the merger of CNS drug discovery pro-
grams with parallel efforts in CNS drug targeting. Prog-
ress in CNS drug targeting is enabled by an understand-
ing of the molecular and cellular biology of BBB
transport processes.
